Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMIX
stocks logo

AMIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast AMIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMIX is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast AMIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMIX is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.870
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 0.870
sliders
Low
5.00
Averages
5.00
High
5.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Autonomix Medical Inc (AMIX.O) is -0.46, compared to its 5-year average forward P/E of -1.54. For a more detailed relative valuation and DCF analysis to assess Autonomix Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.54
Current PE
-0.46
Overvalued PE
0.65
Undervalued PE
-3.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

AMIX News & Events

Events Timeline

(ET)
2025-11-26
17:06:08
Autonomix submits filing to offer 13.5 million shares of common stock for shareholders.
select
2025-11-18 (ET)
2025-11-18
09:55:35
Autonomix sets price for 4.5 million shares at $1.11 in private placement.
select
2025-11-17 (ET)
2025-11-17
08:14:04
Autonomix Releases Findings from Exploratory Subgroup Analysis of PoC Study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-26Newsfilter
Autonomix Medical Advances Nerve-Targeted Treatment Technology
  • Intellectual Property Protection: In the latest CEO Corner, Autonomix CEO Brad Hauser emphasized the company's strategy to strengthen its intellectual property, which will safeguard its competitive advantage in the medical device market and ensure ongoing leadership.
  • New Market Exploration: The company plans to expand its nerve-targeted treatment technology beyond pancreatic cancer to include cardiovascular, pulmonary diseases, and chronic pain, a strategic shift that could open new revenue streams and enhance market share.
  • Technological Innovation: Autonomix's microchip sensing array technology is expected to enable unprecedented transvascular diagnosis and treatment capabilities, significantly improving the diagnosis and treatment of peripheral nervous system diseases and meeting market demand for high-sensitivity technologies.
  • Clinical Trial Progress: The company is currently conducting preliminary clinical trials focused on pancreatic cancer, and if successful, it will provide patients with a reliable pain management solution, further solidifying its market position in nerve treatment.
[object Object]
Preview
3.5
11-26Globenewswire
Autonomix Medical Advances Nerve-Targeted Treatment Technology
  • Intellectual Property Protection: Autonomix CEO Brad Hauser emphasized the importance of strengthening intellectual property to protect the company's platform, which will provide legal assurance for future technological advancements and ensure a competitive edge in the medical device market.
  • New Market Exploration: The company plans to expand its initial focus from pancreatic cancer to new areas such as cardiovascular and pulmonary diseases as well as chronic pain, a strategic shift that not only increases potential market size but also enhances the company's influence in treating various conditions.
  • Technological Innovation: Autonomix's microchip sensing array technology is expected to enable high-sensitivity detection of neural signals, making transvascular diagnosis and treatment of nervous system diseases possible for the first time, thereby offering more effective treatment options for patients.
  • Clinical Trial Progress: The company is currently conducting preliminary clinical trials focused on pancreatic cancer, which, if successful, will provide a reliable pain management solution for patients while laying the groundwork for future applications in cardiology and hypertension.
[object Object]
Preview
2.0
11-18Benzinga
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.

  • Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.

  • Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Autonomix Medical Inc (AMIX) stock price today?

The current price of AMIX is 0.87 USD — it has decreased -0.23 % in the last trading day.

arrow icon

What is Autonomix Medical Inc (AMIX)'s business?

Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.

arrow icon

What is the price predicton of AMIX Stock?

Wall Street analysts forecast AMIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMIX is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Autonomix Medical Inc (AMIX)'s revenue for the last quarter?

Autonomix Medical Inc revenue for the last quarter amounts to -7.53M USD, increased 165.66 % YoY.

arrow icon

What is Autonomix Medical Inc (AMIX)'s earnings per share (EPS) for the last quarter?

Autonomix Medical Inc. EPS for the last quarter amounts to -3817000.00 USD, increased 139.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Autonomix Medical Inc (AMIX)'s fundamentals?

The market is revising No Change the revenue expectations for Autonomix Medical, Inc. (AMIX) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.00%.
arrow icon

How many employees does Autonomix Medical Inc (AMIX). have?

Autonomix Medical Inc (AMIX) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Autonomix Medical Inc (AMIX) market cap?

Today AMIX has the market capitalization of 5.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free